Financial Snapshot
Revenues
Revenues
Revenue YoY Change
Revenues
Expenses
Cost Of Revenues
Gross Profit
Gross Profit Margin
Gross Profit
Selling, General & Admin Expense
Research & Development
Depreciation, Depletion & Amortization
SGA Expense to Gross Profit Ratio
R&D To Gross Profit Ratio
DDA To Gross Profit Ratio
Operating Expenses Total
Operating Profits/Loss
Operational Expenses
Interest Expenses
Interest Expenses To Operating Income %
Other Expense/Income
Interest & Other Expense/Income
Income/Loss
Pretax Income
Income Tax
Net Profits/Loss
Pretax Income YoY Change
Income Tax Rate
Net Profits/Loss YoY Change
Basic EPS
Net Income To Revenue Ratio
Pretax & Net Income
Assets & Liabilities
Cash & Short-Term Investments
Cash & Equivalents
Cash To Operating Expenses Ratio
Inventory
Receivables
Total Short-Term Assets
Property, Plant And Equipment
Long-Term Investments
Total Long-Term Assets
Total Assets
Net Income To Total Assets Percentage
Accounts Payable
Short-Term Debt
Long Term Debt Due
Total Short-Term Liabilities
Long-Term Debt
Other Long-Term Liabilities
Total Long-Term Liabilities
Total Liabilities
Short-Term To Long-Term Debt Ratio
Short-Term Assets To Debt Ratio
Long-Term Debt To Net Income Ratio
Assets & Liabilities
Ownership
Basic Shares Outstanding
Diluted Shares Outstanding
Preferred Stock
Treasury Stock Shares
Stock Issuance & Repurchase
Ownership Data
Return On Shareholders' Equity
Book Value
Free Cash Flow
Free Cash Flow YoY
Free Cash Flow Margin
Dividends
Dividends
Stock Price
About POINT Biopharma Global Inc.
POINT Biopharma Global, Inc. is a radiopharmaceutical company. The company is headquartered in Indianapolis, Indiana and currently employs 129 full-time employees. The company went IPO on 2020-07-10. The firm is engaged in building a platform for the clinical development and commercialization of radioligands that fight cancer. The firm is focused on transforming precision medicine by combining a portfolio of radiopharmaceutical assets, a seasoned management team, a pipeline, in-house manufacturing capabilities, and secured supply for rare medical isotopes like actinium-225 (Ac) and lutetium-177 (Lu). Its pipeline consists of late-stage programs in prostate cancer (PNT2002) and neuroendocrine tumors (PNT2003). Its Lu-PNT2002 is a late-stage prostate-specific membrane antigen (PSMA) targeted radioligand therapy. Its Lu-PNT2003 is a late-stage somatostatin-targeted radioligand in development for the treatment of neuroendocrine tumors. Its PNT2004 is a fibroblast activation protein-a (FAP) targeting program being developed for use in multiple tumor types.
Industry: Pharmaceutical Preparations Peers: CareDx, Inc. Cogent Biosciences, Inc. Editas Medicine, Inc. Erasca, Inc. Forma Therapeutics Holdings, Inc. GERON CORP Keros Therapeutics, Inc. Kura Oncology, Inc. REGENXBIO Inc.
